AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01259063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and Intravesical Gemcitabine
Description: Phase I: Everolimus will be adm as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be adm at 10 mg daily the dose determined in Phase I. Pts will receive a dose of 2000 mg of intravesical gemcitabine twice a week (72-96 +8 hours between doses) for 3 weeks for a total of 6 treatments in course 1. After 1 week of rest from intravesical gemcitabine, course 2 will be administered, provided the treating physician notes acceptable pt tolerance. The total number of intravesical instillations will be 12. There will be no dose modifications to gemcitabine; however, pts will be allowed to skip gemcitabine doses if needed, per the treating physician's discretion. Missed or skipped doses of gemcitabine will not be repeated. The pt will receive as many instillations as tolerable up to the maximum of 12 instillations.
Study NCT05512897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinea plane block
Description: in assistance of ultrasound for visualization anesthetic injection point. 30-40 mL Ropivacaine 0.375% plus 2 mg Dexamethasone administered on each side will be administered between thoracic transversus process and longitudinal spine muscle
Study NCT00995761 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Docetaxel and Cisplatin
Description: splitted administration of docetaxel and cisplatin.
Study NCT04398771 — intervention group
Intervention type: DRUG
Intervention: Rosuvastatin/Valsartan
Description: Rovatitan QD for 12 weeks
Study NCT01857219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai chi
Study NCT01942928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual NHS Care
Description: Usual NHS care is provided by a health visitor who will diagnose excessively crying infants/infants with colic in the first instance. Parents usually will then have the opportunity to consult their health visitor when needed. The health visitor will provide support and advice on how to manage the condition within their professional remit.
Study NCT01942928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Therapy
Description: Osteopathic treatment will be provided by experienced osteopaths once a week for up to four weeks, depending on needs. Treatment will be individualised, according to clinical findings, and involves using standard cranial osteopathic techniques. All parents will be able to ask questions.
Study NCT03075787 — intervention group
Intervention type: DEVICE
Intervention: standard 24-h ambulatory polysomnography
Description: A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
Study NCT03043313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given intravenously (into the vein; IV)
Study NCT03043313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Given orally
Study NCT02318732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APPS intervention
Description: Contact with and recovery of firearms from individuals who are prohibited from possessing them
Study NCT02318732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: APPS intervention
Description: Contact with and recovery of firearms from individuals who are prohibited from possessing them
Study NCT01991808 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT02174965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniHip (Corin U.K.)
Description: MiniHip (Corin U.K.) femoral component
Study NCT02174965 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metafix (Corin, U.K)
Description: Metafix (Corin, U.K) conventional cementless stem
Study NCT01544205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI-based neurofeedback
Description: 5 sessions lasting one hour each
Study NCT01544205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fMRI-based neurofeedback
Description: 5 sessions lasting one hour each
Study NCT04426734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dextenza Dexamethasone Implant
Description: The area of the punctum is first anesthetized with eye drops. A localized injection of lidocaine in perform once the surface of the punctum is numbed with the eyedrop. After 5-10 minutes, the corner of the eyelid and the region of the punctum will be fully anesthetic. The upper and lower punctum are then dilated with a punctum dilator to facilitate the insertion of the DEXTENZA medication. The DEXTENZA medication is then inserted using smooth forceps into the dilated opening of the upper and lower punctum. Once the DEXTENZA is inserted into the both the upper and lower punctum, the procedure is down. No repeated insertion of the DEXTENZA is required for the study.
Study NCT04426734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Prednisolone Acetate 1%
Description: Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of~8x/day week 1 4x/day week 2 2x/day week 3~1x/day week 4~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30
Study NCT02928679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg (Saxenda)
Study NCT02928679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide 3 mg placebo
Study NCT01292135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: 420 mg daily
Study NCT03330925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ElastiMed's SACS
Description: A wearable medical device that improve circulation using smart materials
Study NCT02425410 — intervention group
Intervention type: OTHER
Intervention: Collect of data on viral environment of T1D patients
Description: Questionnaires on viral events during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
Study NCT02425410 — intervention group
Intervention type: GENETIC
Intervention: Collect of blood samples for DNA extraction and genetic characterization (GWAS)
Description: Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotypage)
Study NCT03945383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with IPL device
Description: Treatment with IPL device
Study NCT01102114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX Vaccine
Description: NicVAX vaccine given 6 times over 6 months
Study NCT01102114 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Placebo vaccine given 6 times over 6 months
Study NCT01739998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: functional oil
Study NCT01739998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03052790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manually instrumented total knee arthroplasty
Description: Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
Study NCT03052790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic assisted total knee arthroplasty
Description: Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
Study NCT04146181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
Study NCT02015273 — intervention group
Intervention type: DEVICE
Intervention: easypod™
Description: Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
Study NCT01897025 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real-tDCS with MI-BCI
Description: As in Arm Description
Study NCT01897025 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: real-tDCS with MI-BCI
Description: As in Arm Description
Study NCT03969381 — intervention group
Intervention type: RADIATION
Intervention: diffusion weighted magnetic resonance image in lymphoma
Description: compare between result of positron emission tomography /computed tomography and diffusion weighted imaging in followup of lymphoma
Study NCT02947893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule(s) Once a Day by Mouth
Description: 1 capsule of Placebo once a day for 6 months followed by 2 capsules of Placebo for another 6 months
Study NCT02947893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib Capsule(s) Once a Day by Mouth
Description: 1 capsule of Nilotinib 150 mg once a day for 6 months followed by 2 capsules of Nilotinib (150 mg each capsule = 300 mb total) for the subsequent 6 months
Study NCT04366349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: melrilimab (GSK3772847) 70 milligram (mg)
Description: melrilimab (GSK3772837) will be available at a dose strength of 70 milligram per milliliter (mg/mL) in a 3 milliliter (mL) glass vial.
Study NCT04366349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: melrilimab (GSK3772847) 140 milligram (mg)
Description: Two doses of melrilimab (GSK3772837) 70 milligram per milliliter (mg/mL) will be administered to achieve a dose strength of 140 milligram per milliliter (mg/mL)
Study NCT04366349 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match melrilimab (GSK3772847) will be available in the form of solution for injection in a 3 milliliter (mL) glass vial.
Study NCT00537134 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embolization, coiling
Description: Endovascular embolization with platinum coils
Study NCT04459013 — intervention group
Intervention type: OTHER
Intervention: Salivary samples
Description: The salivary samples will be collected at 5 defined times
Study NCT02952378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumins
Description: Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.
Study NCT04037618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-EYP001a
Description: Oral drinking suspension
Study NCT03420170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Exercise Integrated Education
Description: Aerobic exercise Wheelchair propelling, boxing, hand cycling (2 rounds)~1. 3 mins. exercise and 2 mins. rest~2. Increased to 4.5 mins. and 30 sec. rest~Strengthening exercise:~Vertical chest press, butterfly press; vertical row and wide lattissimus pull down 3 sets, 10 reps. and 2 min rest between sets, moderate to vigorous intensity (50% of 1 RM)~Educational intervention:~The educational intervention for exercise self-efficacy and physical activity level (2 hours a week for 8 weeks during in rehabilitation and once a month for 8 weeks after discharge from rehabilitation)
Study NCT03269526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR BATs after standard of care chemo
Description: Subjects will receive one dose of standard of care chemotherapy prior to twice weekly or weekly infusions of EGFR BATs for 4 weeks.
Study NCT03957551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib is an oral small molecule potent inhibitor of pro-invasive receptor tyrosine kinases (RTKs).~Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day, in combination with pembrolizumab. The drug is taken continuously for 21 days or 3 weeks. This period of time is defined as one treatment cycle.
Study NCT03957551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized antibody which will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks in combination with cabozantinib.
Study NCT03626727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate Oral Solution [Xyrem]
Description: Xyrem will be given to participants to determine if it is effective in treating post-traumatic narcolepsy and post-traumatic hypersomnia
Study NCT02620839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO
Study NCT02620839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00609102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule BID
Study NCT00609102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: n-aceylcysteine
Description: 450 mgm BID
Study NCT00712751 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Participants randomized to the Usual Care arm will receive standard care . For women, this is defined as the care that participants who are not in the intervention receive; we will ask these participants what psychosocial care they are receiving to track usual care. For men, usual care will consist of a standardized referral to the men's Sexual Medicine Program at MSKCC and written information in the form of the American Cancer Society (ACS) booklet on Sexuality after Cancer. Individuals randomized to Usual Care will not receive any additional counseling sessions from the study interventionists until they are done with the follow up interviews and then it will be offered to them. Follow up questionnaires will assess all study participants at 4 and 8 months after baseline.
Study NCT00712751 — intervention group
Intervention type: BEHAVIORAL
Intervention: CSI-SH- Cancer Survivorship Intervention
Description: This involves four 1-hour individual sessions with three additional telephone booster/review sessions provided in between the four sessions. Sessions can be completed in person or conducted over the phone. Although every effort will be made to complete the booster session in between counseling sessions, if the patient is unavailable to complete the booster calls they may be skipped. Sessions one and two will focus on rehabilitation techniques and tools will be provided and discussed with participants during these first two sessions.
Study NCT03023449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Inhaled Nitric Oxide gas
Study NCT04710901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: uTECH + YMHP
Description: uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention. In addition, participants in this arm will also receive the YMHP intervention, which provides a four-session, evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in the study.
Study NCT04710901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: YMHP
Description: YMHP intervention provides a four-session evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in this study. Months 3-12 are inactive.
Study NCT04710901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: uTECH
Description: uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention.
Study NCT04208919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor-derived DCreg
Description: Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to the start of immunosuppression weaning.
Study NCT03935984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitonin
Description: Treatment with calcitonin to lower high calcium levels prior to reimaging exam
Study NCT03355976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg flat dose every 2 weeks
Study NCT03355976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1mg/kg every 6 weeks
Study NCT03550027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PleurX
Description: Positioning of drainage PleurX
Study NCT03550027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pleurocath
Description: Positioning of drainage Pleurocath
Study NCT04065139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Description: After insufflation of a 12 mmHg of capnoperitoneum at 37°C, two balloons safety trocars (10 and 12mm) are inserted into the abdominal wall. Injection of Doxorubicin (2.1 mg/m2 in 50 ml NaCl 0.9%) and Cisplatin (10.5 mg/m2 body surface in 150 ml NaCl 0.9%) with a flow rate of 0.7ml/s, the therapeutic capnoperitoneum is maintained for 30 min at body temperature.
Study NCT04065139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy
Description: Patient will receive standard poly chemotherapy proposed by the oncologist or any new standard validated during the study, until progression or toxicity.
Study NCT02546167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-BCMA
Study NCT04052334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIL
Description: Participants will receive an infusion of Tumor-infiltrating lymphocytes (TIL) after tumor resection and TIL product is generated.
Study NCT04052334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously (IV) bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, beginning approximately 8 to 16 hours after T-cell infusion.
Study NCT04052334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 30 minutes for 5 days, prior to T-Cell infusion
Study NCT04052334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion
Study NCT04033796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25,000 IU
Description: Vitamin-D3 supplementation providing 25,000 IU administered orally every two months (equivalent to \~400 IU/d);
Study NCT04033796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 50,000 IU
Description: Vitamin-D3 supplementation providing 50,000 IU administered orally every two months (equivalent to \~800 IU/d);
Study NCT04033796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo (administered orally every two months) supplementation control group.
Study NCT01088568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the implantation of toric implantable collamer lens
Description: perform the implantation of toric implantable collamer lens for both eyes
Study NCT01088568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: customized laser-assisted in situ keratomileusis
Description: perform Q-factor customized laser-assisted in situ keratomileusis for both eyes
Study NCT04236427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angong Niuhuang Wan
Description: Angong Niuhuang Wan 3g
Study NCT04236427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Angong Niuhuang Wan Placebo
Description: Angong Niuhuang Wan Placebo 3g
Study NCT02856412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Veterans Group Exercise (VGX)
Description: Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.
Study NCT02856412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Illness Management and Recovery
Description: Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.